merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Less oversight and safety concerns</answer>

<question_number>2</question_number>
<answer>By offering a similar product directly to consumers</answer>

<question_number>3</question_number>
<answer>Lack of FDA oversight on safety, quality, and effectiveness</answer>

<question_number>4</question_number>
<answer>To undercut compounded versions and regain market share</answer>

<question_number>5</question_number>
<answer>It allows compounding pharmacies to produce alternative versions</answer>

<question_number>6</question_number>
<answer>Removing third-party supply chain entities for transparent pricing</answer>

<question_number>7</question_number>
<answer>Increased risk for older patients due to lack of coverage</answer>

<question_number>8</question_number>
<answer>Positioning its vials as a safer, FDA-approved alternative</answer>

<question_number>9</question_number>
<answer>FDA listing as "in shortage"</answer>

<question_number>10</question_number>
<answer>Lower pricing</answer>

<other></other>